Unusual DNA binding modes for metal anticancer complexes

Biochimie

Volumn 91, Issue 10, 2009, Pages 1198-1211

  Pizarro, Ana M ^a   Sadler, Peter J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

DNA; Metallodrug; Organometallic complex; Photoactivation; Transition metals

Indexed keywords

BBR 3464; CARBOPLATIN; CISPLATIN; EPTAPLATIN; FFC 14A; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; INDAZOLIUM TRANS[(TETRACHLORIDE)BIS(1H INDAZOLE)]RUTHENATE; IPROPLATIN; LOBAPLATIN; METAL COMPLEX; NEDAPLATIN; OSMIUM DERIVATIVE; OXALIPLATIN; PLATINUM COMPLEX; RUTHENIUM COMPLEX; SATRAPLATIN; TETRAPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CLINICAL TRIAL; COLON CARCINOMA; CRYSTAL STRUCTURE; DNA ADDUCT; DNA DAMAGE; DRUG DNA BINDING; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG STRUCTURE; HEAD AND NECK CANCER; HUMAN; LYMPHOMA; MELANOMA; METAL BINDING; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PHOTOACTIVATION; REVIEW; SOLID TUMOR; TESTIS CANCER; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOPLATINUM COMPOUNDS; PHOTOCHEMISTRY; PRODRUGS;

EID: 69749111264     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.03.017     Document Type: Review

References (173)

1. Komeda S., Moulaei T., Woods K.K., Chikuma M., Farrell N.P., and Williams L.D. A third mode of DNA binding: phosphate clamps by a polynuclear platinum complex. J. Am. Chem. Soc. 128 (2006) 16092-16103
2. Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug (1999), Verlag Helvetica Chimica Acta, Zurich 563 pp.
3. Bednarski P.J., Mackay F.S., and Sadler P.J. Photoactivatable platinum complexes. Anti-Cancer Agents Med. Chem. 7 (2007) 75-93
4. Ronconi L., and Sadler P.J. Unprecedented carbon-carbon bond formation induced by photoactivation of a platinum(iv)-diazido complex. Chem. Commun. (2008) 235-237
5. Phillips Hazel I.A., Ronconi L., and Sadler Peter J. Photoinduced reactions of cis, trans, cis-[Pt(IV)(N3)2(OH)2(NH3)2] with 1-methylimidazole. Chem. Eur. J. 15 (2009) 1588-1596
6. Bratsos I., Jedner S., Gianferrara T., and Alessio E. Ruthenium anticancer compounds: challenges and expectations. Chimia 61 (2007) 692-697
7. Hartinger C.G., Jakupec M.A., Zorbas-Seifried S., et al. KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodiversity 5 (2008) 2140-2155
8. Peacock A.F.A., and Sadler P.J. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Chem. Asian J. 3 (2008) 1890-1899
9. Rosenberg B., Vancamp L., and Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205 (1965) 698-699
10. Harder H.C., and Rosenberg B. Inhibitory effects of antitumor platinum compounds on DNA, RNA, and protein syntheses in mammalian cells in vitro. Int. J. Cancer 6 (1970) 207-216
11. Howle J.A., and Gale G.R. Cis-dichlorodiammineplatinum(II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol. 19 (1970) 2757-2762
12. Knox R.J., Friedlos F., Lydall D.A., and Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46 (1986) 1972-1979
13. Pascoe J.M., and Roberts J.J. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand crosslinking and cytotoxic properties of platinum(II) compounds. Biochem. Pharmacol. 23 (1974) 1345-1357
14. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 22 (1983) 3927-3933
15. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25 (1986) 3912-3915
16. Pinto A.L., and Lippard S.J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta 780 (1985) 167-180
17. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis. In: Lippert B. (Ed). Cisplatin (1999), Verlag Helvetica Chimica Acta, Zurich 111-134
18. Ohndorf U.M., and Lippard S.J. Structural aspects of Pt-DNA adduct recognition by proteins. In: Siede W., Kow Y.W., and Doetsch P.W. (Eds). DNA Damage Recognition (2006), Taylor & Francis, New York pp. 239-261
19. Jamieson E.R., and Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99 (1999) 2467-2498
20. Jennerwein M., and Andrews P.A. Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab. Dispos. 23 (1995) 178-184
21. Boreham C.J., Broomhead J.A., and Fairlie D.P. A platinum-195 and nitrogen-15 NMR study of the anticancer drug cis-diamminedichloroplatinum(II) and its hydrolysis and oligomerization products. Aust. J. Chem. 34 (1981) 659-664
22. Miller S.E., and House D.A. The hydrolysis products of cis-dichlorodiammineplatinum(II). 2. The kinetics of formation and anation of the cis-diamminedi(aqua)platinum(II) cation. Inorg. Chim. Acta 166 (1989) 189-197
23. Berners-Price S.J., Frenkiel T.A., Frey U., Ranford J.D., and Sadler P.J. Hydrolysis products of cisplatin: pKa determinations via [1H, 15N] NMR spectroscopy. J. Chem. Soc., Chem. Commun. (1992) 789-791
24. Davies M.S., Berners-Price S.J., and Hambley T.W. Rates of platination of AG and GA containing double-stranded oligonucleotides: insights into why cisplatin binds to GG and AG but not GA sequences in DNA. J. Am. Chem. Soc. 120 (1998) 11380-11390
25. Legendre F., Bas V., Kozelka J., and Chottard J.C. A complete kinetic study of GG versus AG plantination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species. Chem. Eur. J. 6 (2000) 2002-2010
26. Vinje J., Sletten E., and Kozelka J. Influence of dT20 and [d(AT)10]2 on cisplatin hydrolysis studied by two-dimensional [1H,15N] HMQC NMR spectroscopy. Chem. Eur. J. 11 (2005) 3863-3871
27. Davies M.S., Berners-Price S.J., and Hambley T.W. Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg. Chem. 39 (2000) 5603-5613
28. Kozelka J., Legendre F., Reeder F., and Chottard J.C. Kinetic aspects of interactions between DNA and platinum complexes. Coord. Chem. Rev. 190-192 (1999) 61-81
29. Martin R.B. Platinum complexes: hydrolysis and binding to N(7) and N(1) of purines. In: Lippert B. (Ed). Cisplatin (1999), Verlag Helvetica Chimica Acta, Zurich 183-205
30. Berners-Price S.J., and Appleton T.G. The chemistry of cisplatin in aqueous solution. In: Kelland L.R., and Farrell N.P. (Eds). Platinum-based Drugs in Cancer Therapy (2000), Humana Press Inc., Totowa 3-35
31. Hambley T.W. Platinum binding to DNA: structural controls and consequences. J. Chem. Soc., Dalton Trans. (2001) 2711-2718
32. Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?. Chem. Rev. 99 (1999) 2499-2510
33. Caradonna J.P., Lippard S.J., Gait M.J., and Singh M. The antitumor drug cis-dichlorodiammineplatinum forms an intrastrand d(GpG) crosslink upon reaction with [d(ApGpGpCpCpT)]2. J. Am. Chem. Soc. 104 (1982) 5793-5795
34. Filipski J., Kohn K.W., and Bonner W.M. The nature of inactivating lesions produced by platinum(II) complexes in phage l DNA. Chem. Biol. Interact. 32 (1980) 321-330
35. Fichtinger-Schepman A.M.J., Van der Veer J.L., Den Hartog J.H.J., Lohman P.H.M., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24 (1985) 707-713
36. Fichtinger-Schepman A.M., van Oosterom A.T., Lohman P.H., and Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 47 (1987) 3000-3004
37. Hambley T.W. Modelling the interaction of cisplatin with DNA. Drug. Des. Deliv. 3 (1988) 153-158
38. Struik A.F., Zuiderwijk C.T.M., Van Boom J.H., Elding L.I., and Reedijk J. Guanine-O6 methylation reduces the reactivity of d(GpG) towards platinum complexes. J. Inorg. Biochem. 44 (1991) 249-260
39. Baik M.H., Friesner R.A., and Lippard S.J. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine?. J. Am. Chem. Soc. 125 (2003) 14082-14092
40. Sullivan S.T., Ciccarese A., Fanizzi F.P., and Marzilli L.G. A rare example of three abundant conformers in one retro model of the cisplatin-DNA d(GpG) intrastrand cross link. Unambiguous evidence that guanine O6 to carrier amine ligand hydrogen bonding is not important. Possible effect of the Lippard base pair step adjacent to the lesion on carrier ligand hydrogen bonding in DNA adducts. J. Am. Chem. Soc. 123 (2001) 9345-9355
41. Sherman S.E., Gibson D., Wang A.H.J., and Lippard S.J. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2{d(pGpG)}]. Science 230 (1985) 412-417
42. Takahara P.M., Rosenzweig A.C., Frederick C.A., and Lippard S.J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377 (1995) 649-652
43. Gelasco A., and Lippard S.J. NMR solution structure of a DNA dodecamer duplex containing a cis-Diammineplatinum(II) D(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37 (1998) 9230-9239
44. Brown S.J., Kellett P.J., and Lippard S.J. Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261 (1993) 603-605
45. Huang J.C., Zamble D.B., Reardon J.T., Lippard S.J., and Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 91 (1994) 10394-10398
46. Ohndorf U.M., Rould M.A., He Q., Pabo C.O., and Lippard S.J. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399 (1999) 708-712
47. Kartalou M., and Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. Fund. Mol. Mech. Mut 478 (2001) 1-21
48. Jung Y., and Lippard S.J. Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107 (2007) 1387-1407
49. Guggenheim E.R., Xu D., Zhang C.X., Chang P.V., and Lippard S.J. Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. ChemBioChem 10 (2009) 141-157
50. Cohen S.M., Jamieson E.R., and Lippard S.J. Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. Biochemistry 39 (2000) 8259-8265
51. Vichi P., Coin F., Renaud J.P., Vermeulen W., Hoeijmakers J.H.J., Moras D., and Egly J.M. Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. Embo J. 16 (1997) 7444-7456
52. Jung Y., Mikata Y., and Lippard S.J. Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA. J. Biol. Chem. 276 (2001) 43589-43596
53. Naniwa J., Kigawa J., Akeshima R., et al. Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cancer Sci. 94 (2003) 1099-1103
54. Imamura T., Izumi H., Nagatani G., et al. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J. Biol. Chem. 276 (2001) 7534-7540
55. Sundquist W.I., Lippard S.J., and Stollar B.D. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). Proc. Natl. Acad. Sci. USA 84 (1987) 8225-8229
56. Blommaert F.A., van Dijk-Knijnenburg H.C.M., Dijt F.J., den Engelse L., Baan R.A., Berends F., and Fichtinger-Schepman A.M.J. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34 (1995) 8474-8480
57. Kloft C., Eickhoff C., Schulze-Forster K., Maurer H.R., Schunack W., and Jaehde U. Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA. Pharm. Res. 16 (1999) 470-473
58. Saris C.P., van de Vaart P.J.M., Rietbroek R.C., and Blommaert F.A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17 (1996) 2763-2769
59. Kidani Y., Noji M., and Tashiro T. Antitumor activity of platinum(II) complexes of l,2-diammino-cyclohexane isomers. Jpn. J. Cancer Res. 71 (1980) 637-643
60. Rixe O., Ortuzar W., Alvarez M., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol. 52 (1996) 1855-1865
61. Weiss R.B., and Christian M.C. New cisplatin analogs in development: a review. Drugs 46 (1993) 360-377
62. Raymond E., Chaney S.G., Taamma A., and Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9 (1998) 1053-1071
63. Chaney S.G., and Vaisman A. Specificity of platinum-DNA adduct repair. J. Inorg. Biochem. 77 (1999) 71-81
64. Spingler B., Whittington D.A., and Lippard S.J. 2.4.ANG. Crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg. Chem. 40 (2001) 5596-5602
65. Chaney S.G., Campbell S.L., Bassett E., and Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 53 (2005) 3-11
66. Wu Y., Pradhan P., Havener J., et al. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J. Mol. Biol. 341 (2004) 1251-1269
67. Wu Y., Bhattacharyya D., King C.L., et al. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry 46 (2007) 6477-6487
68. Farrell N., Ha T.T.B., Souchard J.P., Wimmer F.L., Cros S., and Johnson N.P. Cytostatic trans-platinum(II) complexes. J. Med. Chem. 32 (1989) 2240-2241
69. Zakovska A., Novakova O., Balcarova Z., Bierbach U., Farrell N., and Brabec V. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur. J. Biochem. 254 (1998) 547-557
70. Coluccia M., Boccarelli A., Mariggio M.A., et al. Platinum(II) complexes containing iminoethers: a trans platinum antitumor agent. Chem. Biol. Interact. 98 (1995) 251-266
71. Novakova O., Kasparkova J., Malina J., Natile G., and Brabec V. DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res. 31 (2003) 6450-6460
72. Perez J.M., Fuertes M.A., Alonso C., and Navarro-Ranninger C. Current status of the development of trans-platinum antitumor drugs. Crit. Rev. Oncol. Hematol. 35 (2000) 109-120
73. Kasparkova J., Novakova O., Marini V., et al. Activation of trans geometry in bifunctional mononuclear platinum complexes by a Piperidine ligand: mechanistic studies on antitumor action. J. Biol. Chem. 278 (2003) 47516-47525
74. Farrell N.P., De Almeida S.G., and Skov K.A. Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies. J. Am. Chem. Soc. 110 (1988) 5018-5019
75. Sessa C., Capri G., Gianni L., et al. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oncol. 11 (2000) 977-983
76. Brabec V., Kasparkova J., Vrana O., et al. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 38 (1999) 6781-6790
77. Perego P., Caserini C., Gatti L., et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol. 55 (1999) 528-534
78. Pratesi G., Perego P., Polizzi D., et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer 80 (1999) 1912-1919
79. Manzotti C., Pratesi G., Menta E., et al. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res. 6 (2000) 2626-2634
80. Roberts J.D., Peroutka J., and Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J. Inorg. Biochem. 77 (1999) 51-57
81. Davies M.S., Thomas D.S., Hegmans A., Berners-Price S.J., and Farrell N. Kinetic and equilibria studies of the aquation of the trinuclear platinum phase II anticancer agent [{trans-PtCl(NH3)2}2{m-trans-Pt(NH3)2(NH2(CH2)6NH2)2}]4+(BBR3464). Inorg. Chem. 41 (2002) 1101-1109
82. Hegmans A., Berners-Price S.J., Davies M.S., Thomas D.S., Humphreys A.S., and Farrell N. Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. J. Am. Chem. Soc. 126 (2004) 2166-2180
83. Chen H., Parkinson J.A., Morris R.E., and Sadler P.J. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J. Am. Chem. Soc. 125 (2003) 173-186
84. Wheate N.J., and Collins J.G. Multi-nuclear platinum complexes as anti-cancer drugs. Coord. Chem. Rev. 241 (2003) 133-145
85. Wheate N.J., and Collins J.G. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr. Med. Chem. Anti Canc. Agents 5 (2005) 267-279
86. Braddock P.D., Connors T.A., Jones M., Khokhar A.R., Melzack D.H., and Tobe M.L. Structure and activity relations of platinum complexes with antitumor activity. Chem. Biol. Interact 11 (1975) 145-161
87. Bramwell V.H., Crowther D., O'Malley S., et al. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Cancer Treat. Rep. 69 (1985) 409-416
88. Creaven P.J., Pendyala L., and Madajewicz S. Clinical development of iproplatin (CHIP). Drugs Exp. Clin. Res. 12 (1986) 287-292
89. Anderson H., Wagstaff J., Crowther D., et al. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur. J. Cancer Clin. Oncol. 24 (1988) 1471-1479
90. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7 (1989) 1602-1613
91. Schilder R.J., LaCreta F.P., Perez R.P., et al. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. 54 (1994) 709-717
92. Farrell N., Kelland L.R., Roberts J.D., and Van Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 52 (1992) 5065-5072
93. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev. Anticancer Ther. 6 (2006) 973-982
94. Sternberg C.N., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9
95. Turanek J., Kasna A., Zaluska D., et al. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs 15 (2004) 537-543
96. Zak F., Turanek J., Kroutil A., et al. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J. Med. Chem. 47 (2004) 761-763
97. Kozubik A., Horvath V., Svihalkova-Sindlerova L., et al. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Biochem. Pharmacol. 69 (2005) 373-383
98. Sova P., Chladek J., Zak F., et al. Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)]. Int. J. Pharm. 288 (2005) 123-129
99. Sova P., Mistr A., Kroutil A., Zak F., Pouckova P., and Zadinova M. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anti-Cancer Drugs 16 (2005) 653-657
100. Sova P., Mistr A., Kroutil A., Zak F., Pouckova P., and Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anti-Cancer Drugs 17 (2006) 201-206
101. Choi S., Cooley R.B., Hakemian A.S., et al. Mechanism of two-electron oxidation of deoxyguanosine 5'-monophosphate by a platinum(IV) complex. J. Am. Chem. Soc. 126 (2004) 591-598
102. Choi S., Mahalingaiah S., Delaney S., Neale N.R., and Masood S. Substitution and reduction of platinum(IV) complexes by a nucleotide, guanosine 5'-monophosphate. Inorg. Chem. 38 (1999) 1800-1805
103. Choi S., Orbai L., Padgett E.J., Delaney S., and Hakemian A.S. A platinum(IV) complex oxidizes guanine to 8-oxo-guanine in DNA and RNA. Inorg. Chem. 40 (2001) 5481-5482
104. Choi S., Cooley R.B., Voutchkova A., Leung C.H., Vastag L., and Knowles D.E. Oxidation of guanosine derivatives by a platinum(IV) complex: internal electron transfer through cyclization. J. Am. Chem. Soc. 127 (2005) 1773-1781
105. Choi S., Vastag L., Leung C.H., Beard A.M., Knowles D.E., and Larrabee J.A. Kinetics and mechanism of the oxidation of guanosine derivatives by Pt(IV) complexes. Inorg. Chem. 45 (2006) 10108-10114
106. Van der Veer J.L., Ligtvoet G.J., and Reedijk J. Reactions of platinum(IV) amine compounds with 9-methylhypoxanthine at high temperature result in both platinum(II) and platinum(IV) amine adducts. J. Inorg. Biochem. 29 (1987) 217-223
107. Roat R.M., and Reedijk J. Reaction of mer-trichloro(diethylenetriamine)platinum(IV) chloride, (mer-[Pt(dien)Cl3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes. J. Inorg. Biochem. 52 (1993) 263-274
108. Chaney S.G., Gibbons G.R., Wyrick S.D., and Podhasky P. An unexpected biotransformation pathway for tetrachloro-(d, l-trans)-1,2-diaminocyclohexaneplatinum(IV)(tetraplatin) in the L1210 cell line. Cancer Res. 51 (1991) 969-973
109. Brabec V., Vrana O., and Kleinwachter V. Tetravalent platinum complexes can exert their antitumor effect via direct reaction with DNA. Stud. Biophys. 114 (1986) 199-207
110. Novakova O., Kasparkova J., Vrana O., van Vliet P.M., Reedijk J., and Brabec V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry 34 (1995) 12369-12378
111. Defais M., Germanier M., and Johnson N.P. Detection of DNA strand breaks in Escherichia coli treated with platinum(IV) antitumor compounds. Chem. Biol. Interact. 74 (1990) 343-352
112. Hall M.D., and Hambley T.W. Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord. Chem. Rev. 232 (2002) 49-67
113. Rotondo E., Fimiani V., Cavallaro A., and Ainis T. Does the antitumoral activity of platinum(IV) derivatives result from their in vivo reduction?. Tumori 69 (1983) 31-36
114. Blatter E.E., Vollano J.F., Krishnan B.S., and Dabrowiak J.C. Interaction of the antitumor agents cis, cis, trans-Pt(IV)(NH3)2Cl2(OH)2 and cis, cis, trans-Pt(IV)[(CH3)2CHNH2]2Cl2(OH)2 and their reduction products with PM2 DNA. Biochemistry 23 (1984) 4817-4820
115. Van der Veer J.L., Peters A.R., and Reedijk J. Reaction products from platinum(IV) amine compounds and 5'-GMP are mainly bis(5'-GMP)platinum(II) amine adducts. J. Inorg. Biochem. 26 (1986) 137-142
116. Eastman A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem. Pharmacol. 36 (1987) 4177-4178
117. Pendyala L., Cowens J.W., Chheda G.B., Dutta S.P., and Creaven P.J. Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res. 48 (1988) 3533-3536
118. Chaney S.G., Wyrick S., and Till G.K. In vitro biotransformations of tetrachloro(d, l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res. 50 (1990) 4539-4545
119. Kratochwil N.A., Bednarski P.J., Mrozek H., Vogler A., and Nagle J.K. Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. Anti-Cancer Drug Des. 11 (1996) 155-171
120. Kratochwil N.A., and Bednarski P.J. Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodo-Pt(IV)-ethylenediamines. Archiv Der Pharmazie 332 (1999) 279-285
121. P. Müller, PhD thesis, University of Edinburgh (2002).
122. Kasparkova J., Mackay F.S., Brabec V., and Sadler P.J. Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex. J. Biol. Inorg. Chem. 8 (2003) 741-745
123. Heringova P., Woods J., Mackay F.S., Kasparkova J., Sadler P.J., and Brabec V. Transplatin is cytotoxic when photoactivated: enhanced formation of DNA cross-links. J. Med. Chem. 49 (2006) 7792-7798
124. Mackay F.S., Woods J.A., Heringova P., et al. A potent cytotoxic photoactivated platinum complex. Proc. Natl. Acad. Sci. USA 104 (2007) 20743-20748
125. Kelman A.D., Clarke M.J., Edmonds S.D., and Peresie H.J. Biological activity of ruthenium purine complexes. J. Clin. Hematol. Oncol. 7 (1977) 274-288
126. Clarke M.J. Oncological implication of the chemistry of ruthenium. Met. Ions Biol. Syst. 11 (1980) 231-283
127. Mestroni G., Alessio E., Calligaris M., et al. Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethyl sulfoxide. Prog. Clin. Biochem. Med. 10 (1989) 71-87
128. Sava G., Bergamo A., Zorzet S., et al. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer 38 (2002) 427-435
129. Bergamo A., Gagliardi R., Scarcia V., et al. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J. Pharmacol. Exp. Ther. 289 (1999) 559-564
130. Sava G., Capozzi I., Clerici K., Gagliardi G., Alessio E., and Mestroni G. Pharmacological control of lung metastases of solid tumors by a novel ruthenium complex. Clin. Exp. Metastasis 16 (1998) 371-379
131. Morbidelli L., Donnini S., Filippi S., et al. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br. J. Cancer 88 (2003) 1484-1491
132. Rademaker-Lakhai J.M., Van Den Bongard D., Pluim D., Beijnen J.H., and Schellens J.H.M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10 (2004) 3717-3727
133. Vacca A., Bruno M., Boccarelli A., et al. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br. J. Cancer 86 (2002) 993-998
134. Ang W.H., Daldini E., Scolaro C., Scopelliti R., Juillerat-Jeannerat L., and Dyson P.J. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem. 45 (2006) 9006-9013
135. Alessio E., Mestroni G., Bergamo A., and Sava G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem. 4 (2004) 1525-1535
136. Garzon F.T., Berger M.R., Keppler B.K., and Schmaehl D. Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats. Cancer Chemoth. Pharmacol. 19 (1987) 347-349
137. Berger M.R., Garzon F.T., Keppler B.K., and Schmaehl D. Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res. 9 (1989) 761-765
138. Seelig M.H., Berger M.R., and Keppler B.K. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats. J. Cancer Res. Clin. Oncol. 118 (1992) 195-200
139. Galanski M., Arion V.B., Jakupec M.A., and Keppler B.K. Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des. 9 (2003) 2078-2089
140. Hartinger C.G., Zorbas-Seifried S., Jakupec M.A., Kynast B., Zorbas H., and Keppler B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 100 (2006) 891-904
141. Reedijk J. Metal-ligand exchange kinetics in platinum and ruthenium complexes. Significance for effectiveness as anticancer drugs. Platinum Met. Rev. 52 (2008) 2-11
142. Clarke M.J., Zhu F., and Frasca D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 99 (1999) 2511-2533
143. Arion V.B., Reisner E., Fremuth M., et al. Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of Isomeric (1H-1,2,4-Triazole)Ru(III) complexes. Inorg. Chem. 42 (2003) 6024-6031
144. Egger A., Arion V.B., Reisner E., et al. Reactions of potent antitumor complex trans-[RuIIICl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action. Inorg. Chem. 44 (2005) 122-132
145. Jakupec M.A., Reisner E., Eichinger A., et al. Redox-Active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J. Med. Chem. 48 (2005) 2831-2837
146. Reisner E., Arion V.B., Guedes da Silva M.F.C., et al. Tuning of redox potentials for the design of ruthenium anticancer drugs - an electrochemical study of [trans-RuCl4L(DMSO)]- and [trans-RuCl4L2]- complexes, where L = imidazole, 1,2,4-triazole indazole. Inorg. Chem. 43 (2004) 7083-7093
147. Ni Dhubhghaill O.M., Hagen W.R., Keppler B.K., Lipponer K.G., and Sadler P.J. Aquation of the anticancer complex trans-[RuCl4(Him)2]- (Him = imidazole). J. Chem. Soc., Dalton Trans. (1994) 3305-3310
148. Cebrian-Losantos B., Reisner E., Kowol C.R., et al. Synthesis and reactivity of the aquation product of the antitumor complex trans-[RuIIICl4(indazole)2]. Inorg. Chem. 47 (2008) 6513-6523
149. Kapitza S., Pongratz M., Jakupec M.A., et al. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J. Cancer Res. Clin. Oncol. 131 (2005) 101-110
150. Kapitza S., Jakupec M.A., Uhl M., Keppler B.K., and Marian B. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 226 (2005) 115-121
151. Morris R.E., Aird R.E., Murdoch P.d.S., et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J. Med. Chem. 44 (2001) 3616-3621
152. Aird R.E., Cummings J., Ritchie A.A., et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human ovarian cancer. Br. J. Cancer 86 (2002) 1652-1657
153. Dougan S.J., Melchart M., Habtemariam A., Parsons S., and Sadler P.J. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity. Inorg. Chem. 45 (2006) 10882-10894
154. Wang F., Bella J., Parkinson J.A., and Sadler P.J. Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide. J. Biol. Inorg. Chem. 10 (2005) 147-155
155. Melchart M., Habtemariam A., Parsons S., and Sadler P.J. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O, O-chelating ligands. J. Inorg. Biochem. 101 (2007) 1903-1912
156. Wang F., Chen H., Parkinson J.A., Murdoch P.d.S., and Sadler P.J. Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine. Inorg. Chem. 41 (2002) 4509-4523
157. Chen H., Parkinson J.A., Novakova O., et al. Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. Proc. Natl. Acad. Sci. USA 100 (2003) 14623-14628
158. Fernandez R., Melchart M., Habtemariam A., Parsons S., and Sadler P.J. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes. Chem. Eur. J. 10 (2004) 5173-5179
159. Marini V., Christofis P., Novakova O., Kasparkova J., Farrell N., and Brabec V. Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)]. Nucleic Acids Res. 33 (2005) 5819-5828
160. Berners-Price S.J., and Sadler P.J. Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy. Coord. Chem. Rev. 151 (1996) 1-40
161. Liu H.K., Berners-Price S.J., Wang F., et al. Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. Angew. Chem. Int. Ed. 45 (2006) 8153-8156
162. Liu L.H.K., Wang F., Parkinson J.A., Bella J., and Sadler P.J. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes. Chem. Eur. J. 12 (2006) 6151-6165
163. Novakova O., Chen H., Vrana O., Rodger A., Sadler P.J., and Brabec V. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry 42 (2003) 11544-11554
164. Gelasco A., and Lippard S.J. Anticancer activity of cisplatin and related complexes 1 (1999) 1-43
165. Bugarcic T., Novakova O., Halamikova A., et al. Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes. J. Med. Chem. 51 (2008) 5310-5319
166. Melchart M., Habtemariam A., Novakova O., et al. Bifunctional amine-tethered ruthenium(II) arene complexes form monofunctional adducts on DNA. Inorg. Chem. 46 (2007) 8950-8962
167. Kasparkova J., Zehnulova J., Farrell N., and Brabec V. DNA Interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem. 277 (2002) 48076-48086
168. Peacock A.F.A., Habtemariam A., Fernandez R., Walland V., Fabbiani F.P.A., Parsons S., Aird R.E., Jodrell D.I., and Sadler P.J. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. J. Am. Chem. Soc. 128 (2006) 1739-1748
169. Peacock A.F.A., Melchart M., Deeth R.J., Habtemariam A., Parsons S., and Sadler P.J. Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding. Chem. Eur. J. 13 (2007) 2601-2613
170. Peacock A.F.A., Habtemariam A., Moggach S.A., Prescimone A., Parsons S., and Sadler P.J. Chloro half-sandwich osmium(II) complexes: influence of chelated N, N-ligands on hydrolysis, guanine binding, and cytotoxicity. Inorg. Chem. 46 (2007) 4049-4059
171. Peacock A.F.A., Parsons S., and Sadler P.J. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N, O-chelating ligands to achieve cancer cell cytotoxicity. J. Am. Chem. Soc. 129 (2007) 3348-3357
172. van Rijt S.H., Peacock A.F.A., Johnstone R.D.L., Parsons S., and Sadler P.J. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. Inorg. Chem. 48 (2009) 1753-1762
173. Kostrhunova H., Florian J., Novakova O., Peacock A.F.A., Sadler P.J., and Brabec V. DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. J. Med. Chem. 51 (2008) 3635-3643